Skip to main content
. 2015 Apr 27;5(4):e151. doi: 10.1038/nutd.2015.1

Figure 3.

Figure 3

Body composition. Body (a) fat and (c) lean mass during CB1 inverse agonist treatment period, and total (b) fat mass and (d) lean mass gain during the whole 5-week treatment period. Values are expressed as means±s.e.m., n=9–12. White squares, dashed lines and white bars=vehicle-treated WT; black squares, lines and bars=vehicle-treated OE-NPYDβH; white triangles, dashed lines and white dotted bars=AM251-treated WT; black triangles, lines and black dotted bars=AM251-treated OE-NPYDβH. *P<0.05, **P<0.01 comparing different genotypes within one treatment, ##P<0.01 comparing different treatments within one genotype and §P<0.05 comparing different treatments only in WT mice with (a, c) repeated measures ANOVA and post hoc test at certain time point or (b, d) two-way ANOVA.